US OptionsDetailed Quotes
SIGA250417C1000
- 0.00
- 0.000.00%
15min DelayClose Apr 7 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-81.24%PremiumApr 17, 2025Expiry Date4.33Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.28Leverage Ratio--Theta--Rho--Eff Leverage--Vega
SIGA Technologies Stock Discussion
Presidential Medal Winner General Keane Joins SIGA Board to Boost Biodefense Strategy
This is silently worsening, and now we have an administration that is turning its back on science. It pulled away from the WHO. Trump's last term was damaging enough, but this time will be truly disastrous.
1. NFA (Not Financial Advice!)
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 CH (cash on hand); AH (after hours): RTH (regular trading hours); PM (pre market)
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. It’s 2025, those newbies need to read and ed...
Tepoxx (Tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
Wow almost bought in too...
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
phew
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
SIGA Technologies (NASDAQ: SIGA) has entered into an exclusive license agreement with Vanderbilt University for a portfolio of preclinical fully human monoclonal antibodies (mAbs). These mAbs have potential as treatments for a broad range of orthopoxviruses, including smallpox and mpox. The agreement grants SIGA exclusive rights to develop, manufacture...
No comment yet